Johnson & Johnson (JNJ), Dendreon Corporation (DNDN): A Magical Drug that Could Change Lives

Page 1 of 2

The biotech sector is perhaps the most volatile and risk-prone sector in the market, but investors still love it. Medical science is leaping forward and new drugs keep hitting the Street, but the hunt for the “safer and more effective drug” is always on. It’s for this reason that we often see contrarians being rewarded massively for their daring positions. The company in focus is Dendreon Corporation (NASDAQ:DNDN), and here are a few reasons why I think it could prove to be a great investment.

Johnson & Johnson (JNJ)

The magic drug

To begin with, Dendreon has absolutely ridiculous fundamentals. From towering debt/equity to plummeting profitability, it gets filtered out as a poor stock. But history doesn’t ascertain the future, right?

Dendreon Corporation (NASDAQ:DNDN) was able to develop an immunotherapy treatment called Provenge that attacks cancer cells by boosting a person’s immunity. This not only contributes to cancer reduction/remission, but also improves a person’s defense system against common illnesses like the flu or infections. Unlike chemotherapy and other radiation treatments, this is a more natural approach, but also has its share of side effects. Its common side effects include chills and fatigue, but it’s still way better than chemotherapy, which causes hair loss, bleeding, and body aches. Provenge competes with Xtandi, developed by Medivation Inc. (NASDAQ:MDVN), and Zytiga, developed by Johnson & Johnson (NYSE:JNJ).

Studies have shown that prostrate specific serum antigen levels shrank by up to 85% when Xtandi was used for a month. Zytiga springs into action soon after it has been prescribed, but Provenge takes at least 2-3 months to even show signs of recovery. But, the good thing is that Provenge uses immunotherapy, which is considered to have fewer side effects than its peers.

This is indeed a revolutionary breakthrough, and just like any new business model, it, too, had a painfully long fertility period. Shares of Dendreon were continuously hammered as the company reported a streak of lower-than-expected sales of its cancer treatment procedure, Provenge. This, coupled with poor margins, brought financial havoc upon the company. For the recent quarter, the company reported a net loss of $0.26 per share, compared to a profit of $0.26 per share in Q4 2011. Its quarterly revenue also plunged to $85 million, down from $202 million in Q4 2011.

But, the Street was absolutely delighted, as it was expecting a loss of $0.55 per share. Moreover, the company reported annual sales to the tune of $325.3 million, up from $213.5 million in FY11. Its streak of poor sales finally seems to be over. Its peers are also performing well. Medivation’s Xtandi was launched in Sept. 2012. Its first full quarter sales stood at a solid $57 million and the management expects its Xtandi sales to cross $100 million, and even beat the street’s estimates. Johnson & Johnson (NYSE:JNJ) also recorded impressive sales growth of 6.8% for Zytiga, but its relatively weaker FY13 guidance disappointed the street. For FY13, Johnson & Johnson is expecting to earn $5.35-$5.45 per share.

Page 1 of 2
blog comments powered by Disqus
Insider Monkey Headlines
Insider Monkey Small Cap Strategy
Insider Monkey Small Cap Strategy

Insider Monkey beat the market by 52 percentage points in 24 months Click to see monthly returns in table format!

Lists

50 Crazy Facts About Japan You Won’t Believe

Top 10 Least Expensive Hybrid Cars to Save the Planet With

The 10 Biggest ‘Gate’ Controversies in History

The 10 States with the Highest Nursing Shortages Leaving Their Hospitals Depleted

The 10 Best Value Investment Blogs that Every Investor Must Read

The 6 Cheapest Boarding Schools in Europe 2015

The 5 Most Expensive Cars To Insure in the World

The 10 Most Common Genetically Modified Foods

10 Self-Made Billionaires Who Came From Nothing

The 10 Most Expensive Cities to Live in North America

The 13 Most Expensive Headphones in the World to Represent

The Top 20 Wealthiest Soccer Teams in 2014

4 BuzzWorthy Cannabis Stocks And Some Smoking Derivative Plays

The 10 Healthiest Fast Food Chains in America to Dine At

The 5 Most Expensive Cat Food Brands You Can Spoil Your Kitty With

The 6 Best eCommerce Platforms for Small Businesses

The 10 Worst Mistakes an Entrepreneur Can Make

The 5 Most OP Characters in League of Legends to Carry Games and Crush Foes With

The 5 Best Foods to Eat Before Running that Will Help You Pound the Pavement

10 Glaring Plot Holes in The Walking Dead that a Zombie-Filled Bus Could Drive Through

The 5 Biggest Celebrity Stoners Who Love Their Reefer

The 10 Most Overrated Movies Of All Time by Out-of-Touch Critics

Top 6 Least Expensive Cruise Destinations For 2015 that Will Take You to Paradise

10 States with Lowest Substance Abuse Rates in America

The 14 Most Watched TV Finales Ever

The 10 Best Selling Role Playing Games of All Time for PC

10 Most Influential Papers In Economics

Top 8 Biggest Charities in the US

10 Worst Celebrity Career Moves Ever

Top 10 Best Paid Tennis Stars in the World

10 Cities with High Demand for Nurses

6 of the Worst Greeting Card Messages Ever Crafted

How to Make Money in ArcheAge and Build Your Empire

10 Foods To Eat To Lower Cholesterol Levels

The 10 Most Hated Television Characters of All Time

The 30 Worst Halloween Costume Ideas Ever Brought to Horrible Life

10 Vocational Skills in Demand Today with Jobs Waiting to be Filled

10 Best Places to Visit in Central and South America

The 10 Greatest Empires in History Which Nearly Conquered the World

The 6 Cheapest Boarding Schools In America 2015

5 Clear Reasons LoL is Better than DotA, Continues to Rule MOBAs

The Only 9 Teams with a Chance to Win the Super Bowl

The 15 Most Common Phobias in America that Induce Fits of Panic

Top 6 Least Expensive Tourist Destinations in 2014

Jim Goetz, Peter Fenton, Jim Breyer: Top 6 Venture Investors for 2014

Top 15 Billionaires in 2014

5 Pitfalls To Avoid When Buying a Franchise

Top 20 Medical Schools in the US – 2014 Rankings

4 Business Strategies that Turned Jamie Oliver into the World’s Richest Chef

6 Qualities That Make You A Good Team Player

Subscribe

Enter your email:

Delivered by FeedBurner

X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 47.6% in its first year! Wondering How?

Download a complete edition of our newsletter for free!